Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 16, 2009

PerkinElmer Buys GE’s Catalog Radiochemicals, SPA Reagents, and Cytostar-T Plate Assets

  • PerkinElmer has purchased the assets of GE Healthcare’s 3H and 14C Catalog Radiochemicals, Scintillation Proximity Assay (SPA) reagents, and Cytostar-T plate product lines.

    The Catalog Radiochemical products are used for a variety of research applications including screening of potential drug candidates through binding assays. The SPA bead-based, light-emitting assay and Cytostar-T plate technologies enable the automation of high-throughput screening (HTS) processes.

    “We expect that the incorporation of these technologies will strengthen our industry-leading GPCR and kinase research product lines and complement our HTS and research reagent solutions,” says Richard M. Eglen, Ph.D., president, Bio-discovery, PerkinElmer.

    PerkinElmer plans to continue expanding its NEN® radiochemical portfolio. The company’s solutions in radiometric detection include lines of readers, nuclear counters, and other instrumentation.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »